Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas

Lin Zheng, MD\textsuperscript{1}, Hai-Liang Li, MD\textsuperscript{1}, Chen-Yang Guo, MD\textsuperscript{1}, Su-Xia Luo, MD, PhD\textsuperscript{2}

Departments of \textsuperscript{1}Minimal-Invasive Intervention and \textsuperscript{2}Medical Gastroenterology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China

**Objective:** To evaluate the efficacy and prognostic factors associated with transcatheter arterial chemoembolization (TACE) combined with microwave ablation (MWA) versus TACE alone for a large solitary or multinodular hepatocellular carcinomas (HCCs).

**Materials and Methods:** This retrospective study involved 258 patients with a large solitary or multinodular HCCs (not more than 10 tumors) who underwent TACE + MWA (n = 92) or TACE alone (n = 166) between July 2011 and April 2015. Local tumor control, survival outcomes, and complications were compared between the two groups. Prognostic factors for time to progression (TTP) and overall survival (OS) were evaluated by univariate and multivariate analyses.

**Results:** The median duration of follow-up was 21.2 months (range, 4−45 months). The median TTP and OS were 12.5 months and 26.6 months, respectively, for the TACE + MWA group and 6.7 months and 17.1 months, respectively, for the TACE group (\(p<0.001\)). The 1-, 2-, and 3-year OS rates were 85.9, 59.8, and 32.6%, respectively, for the TACE + MWA group and 59.0, 40.4, and 11.4%, respectively, for the TACE group (\(p<0.001\)). The corresponding recurrence rates were 47.8, 78.3, and 94.6% for the TACE + MWA group, respectively, and 74.7, 96.4, and 97.6%, respectively, for the TACE group (\(p<0.001\)). Logistic regression analyses showed that the treatment method, tumor size, and tumor number were significant prognostic factors for TTP and OS.

**Conclusion:** TACE + MWA appears to have more advantages compared to TACE in prolonging OS, with a satisfactory TTP, for inpatients with solitary large or multinodular HCCs. Treatment method, tumor size, and tumor number are significant prognostic factors for TTP and OS. Further randomized, multi-center, prospective trials are required to confirm the findings of this study.

**Keywords:** Hepatocellular carcinoma; Transarterial chemoembolization; Microwave ablation; Combination therapy; Large solitary; Multinodular

---

**INTRODUCTION**

Transcatheter arterial chemoembolization (TACE) is the standard treatment for patients with solitary large (tumor size larger than 5 cm in diameter) hepatocellular carcinomas (HCCs) or multinodular HCCs (1, 2). However, the long-term efficacy of TACE is not satisfactory. In most studies, the complete tumor necrosis rate after TACE was only 10–20% and the median survival time 16–20 months (3–7). Radiofrequency ablation (RFA) is considered a safe and
effective treatment for early-stage HCC (8, 9); however, outcomes are favorable only regarding complete necrosis of tumors smaller than 3 cm (10). Microwave ablation (MWA), a method for performing thermal ablation of HCCs, has the capacity to achieve larger and faster ablations than RFA through maintaining guarded and consistently higher intratumoral temperatures (11).

Hence, alternative treatments strategies aimed at achieving better outcomes in patients with solitary large or multinodular HCCs are being explored. One such strategy is TACE plus MWA. Previous studies reported that TACE plus MWA is much more effective than conventional TACE in patients with large solitary HCCs (12, 13). However, to the best of our knowledge, no study has yet analyzed outcomes after TACE plus MWA in patients with large solitary and multinodular (not more than 10 tumors) HCCs.

The purpose of this study was to evaluate the clinical effectiveness and prognostic factors of TACE plus MWA in the management of large solitary and/or multinodular (not more than 10 tumors) HCCs.

MATERIALS AND METHODS

Patients

Our Institutional Review Board approved the use of clinical data for this retrospective study and the requirement for informed consent was waived. Between July 2011 and April 2015, a search of Henan Cancer Hospital’s our institution’s electronic medical records database identified 593 patients with large solitary or multinodular HCCs (with Child-Pugh class A liver function). A total of 276 patients underwent treatment with TACE+MWA or TACE alone. These two regimens were the main recommended treatments in our tertiary-referral hospital. The diagnoses of HCC were confirmed pathologically or clinically according to the American Association for the Study of Liver Diseases criteria (14). The diagnosis of liver cirrhosis was based on magnetic resonance imaging (MRI) findings, together with compatible clinical features of hypertension in the hepatic portal system, such as esophageal and gastric varices or an enlarged spleen with thrombocytopenia (15).

Inclusion criteria were: 1) aged 18–70 years; 2) Child-Pugh class A liver function; 3) HCC with a single tumor ≥ 5 cm in diameter, or 2–3 tumors with a maximum diameter > 3 cm, or 4–10 tumors regardless of size; and 4) received TACE + MWA or TACE treatment. Exclusion criteria were: 1) diffuse-type HCC; 2) HCC after surgical treatment or liver transplantation; 3) TACE combined with any treatment other than MWA, such as percutaneous ethanol injection, RFA, 125I-seed implantation, or sorafenib; 4) concomitant malignancy; and 5) lost to follow up. The inclusion criteria for ablation were: 1) patients with a large solitary tumor or with two or three nodules, each with a residual active area ≤ 5 cm in diameter after TACE treatment. 2) Patients with 4–10 HCC nodules, each nodule ≤ 3 cm in diameter. Application of these criteria yielded 258 patients who were allocated to the following two groups: TACE + MWA (n = 92) and TACE only (n = 166) (Fig. 1).

Transarterial Chemoembolization

Transcatheter arterial chemoembolization was performed in all patients. After introduction of a 5F-RH catheter (Terumo, Tokyo, Japan) through the femoral artery, hepatic artery angiography was performed and the location, number, size, and blood supply of tumors evaluated. Next, a 2.7F micro-catheter (Terumo) was super-selectively inserted into the arteries feeding the tumors and lobaplatin (50 mg) was infused, followed by slow injection of an emulsion of epirubicin (30 mg) mixed with Lipiodol (5–15 mL). Gelatin sponge particles (150–350 μm; Alicon, Hangzhou, China) were injected until the flow was static and full saturation of the feeding arteries had been achieved (16). Liver and kidney function were evaluated 10 days after TACE prior to administering MWA to patients receiving combined therapy.

Microwave Ablation

Microwave ablation was performed approximately 10 days (range, 7–14 days) after TACE using a 16-G MWA cooled-shaft needle antenna (Eco Medical Equipment, Nanjing, China). The MWA needle was inserted to the proximal tumor margin under CT guidance, while the patient was under general anesthesia. The antenna was advanced to the distal margin through the center of each mass for tumors less than 3.0 cm in diameter. For tumors larger than 3.0 cm, an overlapping ablation technique was used to make sure that the ablation zone covered the entire tumor area. Two or three times MWA were needed for tumors larger than 5.0 cm or multinodular HCCs (4–10 tumors). The microwave power was set at 60–80 watts and the procedure lasted 5–10 minutes. Using real-time CT after the procedure, the final ablation was found to exceed the tumor size by 5 mm. Liver protection, anti-inflammatory, analgesic, and symptomatic treatment were prescribed after the MWA treatment.
Assessment of Therapeutic Efficacy and Follow-Up

One month after each session of TACE treatment or MWA, an abdominal dynamic contrast-enhanced MRI scan was performed to assess the therapeutic response and adverse effects (17). Patients with residual viable or recurrent tumors underwent further TACE or TACE plus MWA, whereas those with no evidence of viable tumors were followed up every 2 months. Serum alpha-fetoprotein (AFP) concentrations and MRI scans were evaluated as part of these follow-up visits. The tumor response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors (18, 19). Local tumor control was assessed by the tumor control rate 6 months after treatment and time to tumor progression (TTP), defined as the interval from the date of commencing treatment to the date of identification of local progression. Overall survival (OS) was calculated from the date of commencing treatment to the date of either death or last follow-up. The tumor response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors (18, 19). Local tumor control was assessed by the tumor control rate 6 months after treatment and time to tumor progression (TTP), defined as the interval from the date of commencing treatment to the date of identification of local progression. Overall survival (OS) was calculated from the date of commencing treatment to the date of either death or last follow-up. Complications were scored in the first treatment session, according to the Society of Interventional Radiology classification (20, 21) i.e., those that necessitated major therapies, or resulted in prolongation of hospital stay, permanent adverse sequelae, or death were considered major complications. All other complications were considered to be minor.

Statistical Analysis

Statistical analysis was performed with a SPSS software package (version 18.0; SPSS Inc., Chicago, IL, USA). Quantitative data were compared by the Student’s t test and categorical variables with the χ² or Fisher test. Survival curves were calculated using the Kaplan-Meier method and compared using a log-rank test. A Cox proportional hazards regression model was used to analyze possible factors influencing tumor progression and OS. The statistical significance was defined as a p value of less than 0.05 (two-sided).

RESULTS

Baseline Characteristics

This study included data on 258 patients, 92 of whom received 166 TACE + MWA treatments (median, 1.9; range, 1–4). A total of 166 patients in the TACE group received 676 TACE monotherapy treatments (median, 4.1; range, 1–13). The median follow-up time was 21.2 months (range, 4–45 months). The patients’ baseline characteristics are presented in Table 1; there was no statistically significant difference between the two groups (p > 0.05).

Local Tumor Control, Progression, and Associated Risk Factors

Rates of complete response (CR), partial response (PR), stable disease (SD) and progressive disease were 58.7% (54/92), 13.0% (12/92), 9.9% (9/92), and 18.4%
(17/92), respectively, in the TACE + MWA group, versus 12.7% (21/166), 29.5% (49/166), 13.3% (22/166), and 44.5% (74/166), respectively, in the TACE group. The total response rate (CR + PR + SD) was 81.5% in the TACE + MWA group versus 55.4% in the TACE group ($p < 0.001$) (Table 2, Figs. 2, 3).

### Table 1. Demographic and Baseline Characteristics of Two Treatment Cohorts

| Variables                      | TACE + MWA (n = 92) | TACE (n = 166) | P     |
|--------------------------------|---------------------|----------------|-------|
| Age (years, mean ± standard deviation) | 53.3 ± 8.2          | 54.6 ± 10.5    | 0.325 |
| Sex (%)                        |                     |                |       |
| Male                           | 79 (85.9)           | 143 (86.1)     | 0.951 |
| Female                         | 13 (14.1)           | 23 (13.9)      |       |
| Cirrhosis (%)                  |                     |                |       |
| Present                        | 63 (68.5)           | 114 (68.7)     | 0.974 |
| Absent                         | 29 (31.5)           | 52 (31.3)      |       |
| Etiology (%)                   |                     |                |       |
| HBV                            | 87 (94.6)           | 155 (93.4)     | 0.704 |
| HCV                            | 5 (5.4)             | 11 (6.6)       |       |
| AFP level (ng/mL, mean ± standard deviation) | 720.4 ± 424.6       | 689.4 ± 391.0  | 0.556 |
| < 400 (%)                      | 36 (39.1)           | 56 (60.9)      | 0.567 |
| ≥ 400 (%)                      | 59 (35.5)           | 107 (64.5)     |       |
| Tumor number (mean ± standard deviation) | 3.2 ± 1.6           | 3.2 ± 1.6      | 0.792 |
| Single target                  | 20                  | 33             | 0.906 |
| 2–3 targets                    | 34                  | 65             |       |
| Multiple targets               | 38                  | 68             |       |
| Overall tumor size (cm, mean ± standard deviation) | 9.1 ± 2.8           | 8.5 ± 2.5      | 0.120 |
| ≤ 10 cm (%)                    | 48 (52.2)           | 94 (56.6)      | 0.491 |
| > 10 cm (%)                    | 44 (47.8)           | 72 (43.4)      |       |

AFP = alpha-fetoprotein, HBV = hepatitis B virus, HCV = hepatitis C virus, MWA = microwave ablation, TACE = transcatheter arterial chemoembolization

### Table 2. Local Tumor Control and Survival of Two Treatment Cohorts

| Parameter                  | TACE + MWA (n = 92) | TACE (n = 166) | Z or $\chi^2$ Value | P     |
|----------------------------|---------------------|----------------|--------------------|-------|
| mRECIST (%)                |                     |                |                    |       |
| CR                         | 58.7 (54/92)        | 12.7 (21/166)  | Z = -6.551         | < 0.001|
| PR                         | 13.0 (12/92)        | 29.5 (49/166)  |                    |       |
| SD                         | 9.9 (9/92)          | 13.3 (22/166)  |                    |       |
| PD                         | 18.4 (17/92)        | 44.5 (74/166)  |                    |       |
| Response rate              | 81.5 (75/92)        | 55.4 (92/166)  | $\chi^2 = 17.662$  | < 0.001|
| Recurrence rate (%)        |                     |                |                    |       |
| 1 year                     | 47.8 (44/92)        | 74.7 (124/166) | Z = -4.766         | < 0.001|
| 2 years                    | 78.3 (72/92)        | 96.4 (160/166) |                    |       |
| 3 years                    | 94.6 (87/92)        | 97.6 (162/166) |                    |       |
| TTP (months)               |                     |                |                    |       |
| Median                     | 12.5                | 6.7            | $\chi^2 = 23.422$  | < 0.001|
| IQR                        | 7.6–22.4            | 4.8–12.0       |                    |       |
| OS rate (%)                |                     |                |                    |       |
| 1 year                     | 85.9 (79/92)        | 59.0 (98/166)  | Z = -4.660         | < 0.001|
| 2 years                    | 59.8 (55/92)        | 40.4 (67/166)  |                    |       |
| 3 years                    | 32.6 (30/92)        | 11.4 (19/166)  |                    |       |
| OS (month)                 |                     |                |                    |       |
| Median                     | 26.6                | 17.1           | $\chi^2 = 28.887$  | < 0.001|
| IQR                        | 13.6–38.7           | 6.4–29.0       |                    |       |

CR = complete response, IQR = inter quartile range, mRECIST = modified Response Evaluation Criteria in Solid Tumors, OS = overall survival, PD = progressive disease, PR = partial response, SD = stable disease, TTP = time to progression
The median TTP was 12.5 months (inter quartile range [IQR], 7.6–22.4 months) in the TACE + MWA group versus 6.7 months (IQR, 4.8–12.0 months) in the TACE group. The cumulative 1-, 2-, and 3-year recurrence rates were 47.8, 78.3, and 94.6%, respectively, in the TACE + MWA group. These rates were significantly lower than the respective recurrence rates of 74.7, 96.4, and 97.6% in the TACE group (p < 0.001) (Table 2, Fig. 4A).

Univariate analysis revealed that an absence of cirrhosis (p = 0.081), three or fewer tumors (p = 0.001), overall tumor size ≤ 10 cm (p < 0.001), and TACE + MWA treatment (p < 0.001) could be correlated to an increase in TTP.

Multivariate analysis by the Cox proportional hazard model revealed that three or fewer tumors (hazard ratio [HR] = 0.748, 95% confidence interval [CI]: 0.579–0.966, p = 0.026), tumor size ≤ 10 cm (HR = 0.410, 95% CI: 0.308–0.546, p < 0.001), and TACE + MWA treatment (HR = 0.349, 95% CI: 0.261–0.466, p < 0.001) were independently associated with an increased HR for TTP (Table 3).

**Overall Survival**

The 1-, 2-, and 3-year OS rates were 85.9, 59.8, and 32.6%, respectively, in the TACE + MWA group. These percentages are significantly higher than the respective survival rates of 59.0, 40.4, and 11.4%, reported for the TACE group (p < 0.001). The median survival time was 26.6 months (IQR, 13.6–38.7 months) in the TACE + MWA versus 17.1 months (IQR, 6.4–29.0 months) in the TACE group (p < 0.001) (Table 2, Fig. 4B).

Overall survival could be correlated to cirrhosis (p = 0.074),
number of tumors \((p = 0.002)\), overall tumor size \((p < 0.001)\),
and TACE + MWA treatment \((p < 0.001)\), as determined
by univariate analysis. Multivariate analysis with the Cox
proportional hazard model indicated that tumor number \((HR = 0.694, 95\% CI: 0.532–0.905, p = 0.007)\), overall tumor
size \((HR = 0.395, 95\% CI: 0.295–0.527, p < 0.001)\), and
TACE + MWA treatment \((HR = 0.294, 95\% CI: 0.214–0.405, p
< 0.001)\) were independent factors for OS (Table 4).

Table 3. Univariate and Multivariate Analyses of Prognostic Factors Associated with Tumor Progression

| Clinicopathological Characteristics | Univariate | Multivariate |
|-------------------------------------|------------|--------------|
|                                     | Mean (IQR) | \(P\)         | HR Value | 95\% CI | \(P\) |
| Age, years                          |            |              |          |        |      |
| < 60                                | 8.6 (5.1–16.4) | 0.530       |          |        |      |
| \geq 60                             | 8.7 (5.4–15.4) |            |          |        |      |
| Sex                                 |            |              |          |        |      |
| Male                                | 8.3 (5.1–17.0) | 0.437       |          |        |      |
| Female                              | 8.7 (6.8–11.9) |            |          |        |      |
| Cirrhosis                           |            |              |          |        |      |
| Absent                              | 9.6 (5.3–17.2) | 0.081       |          |        | 0.247 |
| Present                             | 7.0 (4.9–13.3) |            |          |        |      |
| Etiology                            |            |              |          |        |      |
| HBV                                 | 8.8 (5.2–16.4) | 0.506       |          |        |      |
| HCV                                 | 7.8 (5.0–16.2) |            |          |        |      |
| AFP level (ng/mL)                   |            |              |          |        |      |
| < 400                               | 9.3 (5.3–16.0) | 0.531       |          |        |      |
| \geq 400                            | 8.6 (5.0–16.6) |            |          |        |      |
| Tumor number                        |            |              |          |        |      |
| \leq 3                              | 9.7 (5.4–17.2) | 0.001       | 0.748    | 0.579–0.966 | 0.026 |
| > 3                                 | 6.8 (4.8–11.5) |            |          |        |      |
| Overall tumor size (cm)             |            |              |          |        |      |
| \leq 10                             | 10.7 (5.7–20.0) | < 0.001     | 0.410    | 0.308–0.546 | < 0.001 |
| > 10                                | 6.4 (4.5–11.5) |            |          |        |      |
| Treatment method                    |            |              |          |        |      |
| TACE + MWA                          | 12.5 (7.6–22.4) | < 0.001     | 0.349    | 0.261–0.466 | < 0.001 |
| TACE                                | 6.7 (4.8–12.0) |            |          |        |      |

CI = confidence interval

Fig. 4. Tumor progression rate (A) and overall survival rate (B) of patients in TACE + MWA and TACE alone groups.
Complications
There were no treatment-related deaths in either group. Major complications included liver abscess (n = 1) and subcapsular hematoma (n = 1) in the TACE + MWA group, and upper gastrointestinal bleeding (n = 2) and biloma with abscess (n = 4) in the TACE alone group. Minor complications in both groups included abdominal pain, fever, vomiting, grade 1–2 myelosuppression, and self-limiting pleural effusion. There were no significant differences between the two groups in terms of major and minor complications (p > 0.05) (Table 5).

DISCUSSION
Although HCC is highly malignant, it usually remains undiagnosed until it progresses to multifocal or large

Table 4. Univariate and Multivariate Analyses of Prognostic Factors Associated with Overall Survival

| Clinicopathological Characteristics | Univariate | P | Multivariate | P |
|-------------------------------------|------------|---|--------------|---|
| Mean (IQR)                          |            |   | HR | 95% CI |     |
| Age, years                          |            |   |    |        |     |
| < 60                                | 21.3 (8.4–33.3) | 0.542 | 0.694 | 0.532–0.905 | 0.007 |
| ≥ 60                                | 19.5 (10.2–32.3) |          |   |        |     |
| Sex                                 |            |   |    |        |     |
| Male                                | 21.3 (8.4–34.2) | 0.207 |          |   |     |
| Female                              | 22.5 (15.5–27.8) |          |   |        |     |
| Cirrhosis                           |            |   |    |        |     |
| Absent                              | 24.3 (10.0–34.0) | 0.074 |          |   |     |
| Present                             | 14.2 (7.0–27.8) |          |   |        |     |
| Etiology                            |            |   |    |        |     |
| HBV                                 | 21.3 (8.9–32.4) | 0.374 |          |   |     |
| HCV                                 | 18.6 (8.0–33.2) |          |   |        |     |
| AFP level (ng/mL)                   |            |   |    |        |     |
| < 400                               | 19.0 (9.5–31.1) | 0.202 |          |   |     |
| ≥ 400                               | 21.3 (7.5–33.0) |          |   |        |     |
| Tumor number                        |            |   |    |        |     |
| ≤ 3                                 | 24.2 (11.5–33.7) | 0.002 | 0.694 | 0.532–0.905 | 0.007 |
| > 3                                 | 15.5 (6.5–28.7) |          |   |        |     |
| Overall tumor size (cm)             |            |   |    |        |     |
| ≤ 10                                | 26.5 (13.1–37.0) | < 0.001 | 0.395 | 0.295–0.527 | < 0.001 |
| > 10                                | 14.2 (6.0–25.5) |          |   |        |     |
| Treatment method                    |            |   |    |        |     |
| TACE + MWA                          | 26.6 (13.6–38.7) | < 0.001 | 0.294 | 0.214–0.405 | < 0.001 |
| TACE                                | 17.1 (6.4–29.0) |          |   |        |     |

Table 5. Complications of Two Treatment Cohorts

| Complications                              | TACE + MWA (n = 92) n (%) | TACE (n = 166) n (%) | χ² Value | P |
|--------------------------------------------|---------------------------|----------------------|----------|---|
| Major complications                        |                           |                      |          |   |
| Liver abscess                              | 1 (1.1)                   | NA                   |          |   |
| Subcapsular hematoma                       | 1 (1.1)                   | NA                   |          |   |
| Upper GI bleeding                          | NA                        | 2 (1.2)              |          |   |
| Biloma with abscess                        | NA                        | 4 (1.8)              |          |   |
| Minor complications                        |                           |                      |          |   |
| Abdominal pain                             | 63 (68.5)                 | 118 (71.1)           | 0.192    | 0.661 |
| Fever                                      | 71 (77.2)                 | 123 (74.1)           | 0.301    | 0.584 |
| Vomiting                                   | 36 (39.1)                 | 76 (45.8)            | 1.066    | 0.302 |
| Grade 1–2 myelosuppression                 | 3 (3.2)                   | 6 (3.6)              | 0.022    | 0.882 |
| Self-limiting pleural effusion             | 8 (8.7)                   | 7 (4.2)              | 2.168    | 0.141 |

GI = gastrointestinal, NA = not available
intrahepatic lesions, at which point the patient is ineligible for surgical resection (14, 22). Thus, TACE is the standard treatment for large or multinodular HCCs (23, 24). However, after single or repeated TACE procedures, the tumor-supplying arteries may be occluded and snaking arterioles may have regenerated from the gastric, superior mesenteric, phrenic, and intercostal arteries, among other locations (25, 26), making it difficult to selectively catheterize tumor-feeding arteries to control residual tumor cells. Another reason for treatment failure is failure to completely occlude the tumor-supplying artery because of with the generation of small new collaterals to tumor remnants.

Better local tumor control and OS were achieved with TACE + MWA combination therapy versus TACE monotherapy in patients with Barcelona Clinic Liver Cancer (BCLC) stage A HCCs (27, 28). However, to the best of our knowledge, no studies have analyzed the clinical effectiveness and prognostic factors for survival after TACE and MWA combination therapy in patients with solitary large and multinodular HCCs. In the current study, we compared the treatment benefits of TACE + MWA and TACE alone in 258 patients with large or multiple tumors (not more than 10 tumors) and found that TACE + MWA achieved better tumor response rates, longer TTP and better OS rates in the study subjects. The superiority of TACE + MWA vs. TACE monotherapy may be attributable to: 1) Tumor embolization caused by TACE embolization of tumor vessels by TACE that likely reduced the “cooling effect” of blood flowing through arteries feeding the tumor tumoral arterial blood flow (29); 2) TACE reduced or stabilized the size of large HCCs, facilitating MWA treatment; 3) TACE produced tumor tissue ischemia and inflammatory edema, thus increasing thermal effects of ablation (30); 4) Lipiodol was deposited in disseminating daughter lesions, facilitating their destruction in subsequent CT-guided MWA treatments; and 5) CT-guided MWA destroyed some hypovascular HCCs that were refractory to direct and precise TACE procedures (31).

Our findings suggest that TACE + MWA combination therapy was associated with better objective outcomes and clinical benefits in patients with solitary large or multinodular HCCs, except for diffuse-type lesions.

We found that clinical outcomes such as TTP and OS in patients with a large solitary or multinodular HCCs were associated with tumor size, tumor number, and treatment method in patients with a large solitary or multinodular HCCs. TTP and OS were not significantly influenced by age, sex, AFP concentration, or accompanying cirrhosis. These results are consistent with findings from previous studies (32-35).

It is difficult to achieve complete necrosis of large HCCs with TACE or MWA (11, 36). Leung et al. (37) reported that size of the initial tumor size is a significant prognostic factor for local recurrence of liver malignancies treated by MWA. L et al. (38) studied treatment results in 923 patients with BCLC stage B HCCs. Liu et al. (39) reviewed treatment results in 312 patients with large solitary (> 5 cm) HCCs. They both reported that patients with HCCs ≤ 10 cm in size had significantly higher OS survival rates than those with larger HCCs. Kim et al. (40) found that select patients (with the sum of tumor number and maximum tumor size being no more than 11) benefited most from TACE among patients with BCLC stage B HCC. We found that the TTP and OS of patients with HCCs ≤ 10.0 cm in size were better than those of patients with larger HCCs. These findings were in agreement with similar previous studies and suggest that tumor size is independently associated with TTP and OS of patients with HCC and that patients with tumors of ≤ 10.0 cm in size should be prioritized for TACE and MWA combination treatments.

In this study, we found that patients with three or fewer tumors (with a maximum diameter > 3 cm) had better TTP and OS than those with more than three tumors. Peng et al. (41) reported that tumor number is a significant prognostic factor for recurrence-free survival and OS of patients with HCC treated by TACE + RFA. Higher mortalities due to tumor progression were reported by Yamakado et al. (42) for patients with intermediate-stage HCC and four or more tumors. The number of tumors reportedly predicts the degree of intrahepatic spread (43, 44). Our findings are consistent with these data in suggesting that the number of tumors is independently associated with TTP and OS of HCC patients; thus, TACE + MWA therapy should be recommended to patients with three or fewer tumors.

The present study has certain limitations. First, these data were obtained from a single tertiary-care center. A multicenter study with more patients is needed. Second, this was a retrospective study. A randomized controlled study is needed to confirm our findings. Third, 94% of our patients were positive for hepatitis B virus (HBV), which differs greatly from studies in Europe and the USA. Thus, a study including more HBV-negative patients with HCCs that is needed to confirm our findings.

In conclusions, our findings indicate that combination therapy with TACE + MWA appears to be superior to TACE.
monotherapy in terms of delaying TTP and prolonging OS in patients with solitary large or multinodular (not more than 10 tumors) HCCs. Treatment method, tumor size, and number of tumors are significant prognostic factors for TTP and OS. Further randomized, multi-center, prospective studies are required to confirm the findings of this study in the future. Future randomized, controlled, multi-center, prospective studies are required to confirm our study results.

Acknowledgments

We are thankful to Dr. Wei-Zhong Zhou (PhD) from The First Affiliated Hospital of Nanjing Medical University for providing medical writing assistance.

REFERENCES

1. Kishore S, Friedman T, Madoff DC. Update on embolization therapies for hepatocellular carcinoma. Curr Oncol Rep 2017;19:40
2. Jung YK, Jung CH, Seo YS, Kim JH, Kim TH, Yoo YJ, et al. BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. J Gastroenterol Hepatol 2016;31:467–474
3. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698–711
4. Wang YX, De Baere T, Idée JM, Ballet S. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res 2015;27:96–121
5. Lencioni R. Chemoembolization for hepatocellular carcinoma. Semin Oncol 2012;39:503–509
6. Farinati F, Giacomini A, Yanin V, Giannini E, Trevisani F. TACE treatment in hepatocellular carcinoma: what should we do now? J Hepatol 2012;57:221–222
7. Choi TW, Kim HC, Lee JH, Yu SJ, Kang B, Hur S, et al. The safety and clinical outcomes of chemoembolization in child-pugh class C patients with hepatocellular carcinomas. Korean J Radiol 2015;16:1283–1293
8. Liu PH, Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, et al. When to perform surgical resection or radiofrequency ablation for early hepatocellular carcinoma?: a nomogram-guided treatment strategy. Medicine (Baltimore) 2015;94:e1808
9. Wang X, Hu Y, Ren M, Lu X, Lu G, He S. Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: a time-to-event meta-analysis. Korean J Radiol 2016;17:93–102
10. Bertrand J, Caillol F, Borentain P, Raoul JL, Heyries L, Bories E, et al. Percutaneous hepatic radiofrequency for hepatocellular carcinoma: results and outcome of 46 patients. Hepat Med 2015;7:21–27
11. Abdelaziz AO, Abdelmaksoud AH, Nabeel MM, Shousha HI, Cordie AA, Mahmoud ShH, et al. Transarterial chemoembolization combined with either radiofrequency or microwave ablation in management of hepatocellular carcinoma. Asian Pac J Cancer Prev 2017;18:189–194
12. Xu Y, Shen Q, Wang N, Liu P, Wu P, Peng Z, et al. Percutaneous microwave ablation of 5–6 cm unresectable hepatocellular carcinoma: local efficacy and long-term outcomes. Int J Hyperthermia 2017;33:247–254
13. SI ZM, Wang GZ, Qian S, Qu XD, Yan ZP, Liu R, et al. Combination therapies in the management of large (≥ 5 cm) hepatocellular carcinoma: microwave ablation immediately followed by transarterial chemoembolization. J Vasc Interv Radiol 2016;27:1577–1583
14. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–1022
15. Choe WH, Kim YJ, Park HS, Park SW, Kim JH, Kwon SY. Short-term interval combined chemoembolization and radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol 2014;20:12588–12594
16. Kang HJ, Kim YJ, Kim HC, Jae HJ, Hur S, Chung JW. Does establishing a safety margin reduce local recurrence in subsegmental transarterial chemoembolization for small nodular hepatocellular carcinomas? Korean J Radiol 2015;16:1068–1078
17. Lee EW, Alanis L, Cho SK, Saab S. Yttrium-90 selective internal radiation therapy with glass microspheres for hepatocellular carcinoma: current and updated literature review. Korean J Radiol 2016;17:472–488
18. Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol 2017;66:1166–1172
19. Zhu ZX, Liao MH, Wang XX, Huang JW. Transcatheter arterial chemoembolization plus 131I-labelled metuximab versus transcatheter arterial chemoembolization alone in intermediate/advanced stage hepatocellular carcinoma: a systematic review and meta-analysis. Korean J Radiol 2016;17:882–892
20. Lahat E, Eshkenazy R, Zendel A, Zakai BB, Maor M, Dreznik Y, et al. Complications after percutaneous ablation of liver tumors: a systematic review. Hepatobiliary Surg Nutr 2014;3:317–323
21. Schneeweiss S, Horger M, Ketelsen D, Ioanoviciu SD. [Complications after TACE in HCC - complications after transarterial chemoembolization (TACE) in hepatocellular carcinoma]. Rofo 2015;187:79–82
22. Schlachterman A, Craft WW Jr, Hilgenfeldt E, Mitra A, Cabrera R. Current and future treatments for hepatocellular carcinoma. World J Gastroenterol 2015;21:8478–8491
23. Massani M, Stecca T, Ruffolo C, Bassi N. Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. Updates Surg 2017;69:67–73
24. Liu YS, Ou MC, Tsai YS, Lin XZ, Wang CK, Tsai HM, et al. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma. *Korean J Radiol* 2015;16:125-132

25. Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. *Liver Int* 2010;30:741-749

26. Zhao M, Wang JP, Pan CC, Li W, Huang ZL, Zhang L, et al. CT-guided radiofrequency ablation after transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement. *Eur J Radiol* 2012;81:2717-2725

27. Xu LF, Sun HL, Chen YT, Ni JY, Chen D, Luo JH, et al. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. *J Gastroenterol Hepatol* 2013;28:456-463

28. Lucchina N, Tsetis D, Ierardi AM, Girolando F, Macchi E, Kehagias E, et al. Current role of microwave ablation in the treatment of small hepatocellular carcinomas. *Ann Gastroenterol* 2016;29:460-465

29. Fong ZV, Palazzo F, Needleman L, Brown DB, Eschelman DJ, Chojnacki KA, et al. Combined hepatic arterial embolization and hepatic ablation for unresectable colorectal metastases to the liver. *Am Surg* 2012;78:1243-1248

30. Ni JY, Sun HL, Chen YT, Luo JH, Chen D, Jiang XY, et al. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma. *World J Gastroenterol* 2014;20:17483-17490

31. Kim JW, Kim JH, Won HJ, Shin YM, Yoon HK, Sung KB, et al. Hepatocellular carcinomas 2-3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone. *Eur J Radiol* 2012;81:e189-e193

32. Sun AX, Cheng ZL, Wu PP, Sheng YH, Qu XJ, Lu W, et al. Clinical outcome of medium-sized hepatocellular carcinoma treated with microwave ablation. *World J Gastroenterol* 2015;21:2997-3004

33. Salvalaggio PR, Felga GE, Alves JA, Meirelles RF Jr, Almeida MD, de Rezende MB. Response to transarterial chemoembolization in candidates with hepatocellular carcinoma within Milan criteria does not predict post-transplant disease-free survival. *Transplant Proc* 2014;46:1799-1802

34. Yin X, Zhang L, Wang YH, Zhang BH, Gan YH, Ge NL, et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma. *BMC Cancer* 2014;14:849

35. Jin YJ, Lee JW. Therapeutic priorities for solitary large hepatocellular carcinoma in a hepatitis B virus endemic area; an analysis of a nationwide cancer registry database. *J Surg Oncol* 2017;115:407-416

36. Kawaguchi T, Ohkawa K, Imanaka K, Tamai C, Kawada N, Ikezawa K, et al. Lipiodol accumulation and transarterial chemoembolization efficacy for HCC patients. *Hepatogastroenterology* 2012;59:219-223

37. Leung U, Kuk D, D’Angelica MI, Kinham TP, Allen PJ, DeMatteo RP, et al. Long-term outcomes following microwave ablation for liver malignancies. *Br J Surg* 2015;102:85-91

38. Jianyong L, Lunan Y, Wentao W, Yong Z, Bo L, Tianfu W, et al. Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection? *Medicine (Baltimore)* 2014;93:e180

39. Liu PH, Su CW, Hsu CY, Hsia CY, Lee YH, Huang YH, et al. Solitary large hepatocellular carcinoma: staging and treatment strategy. *PLoS One* 2016;11:e0155588

40. Kim JH, Shim JH, Lee HC, Sung KB, Ko HK, Ko YG, et al. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. *Liver Int* 2017;37:1861-1868

41. Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. *J Clin Oncol* 2013;31:426-432

42. Yamakado K, Miyayama S, Hirotu S, Mizunuma K, Nakamura K, Inaba Y, et al. Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization. *Jpn J Radiol* 2014;32:260-265

43. Zhong JH, Rodriguez AC, Ke Y, Wang YY, Wang L, Li LQ. Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. *Medicine (Baltimore)* 2015;94:e396

44. Dong ZR, Zhang PF, Wang CH, Zhang C, Cai JB, Shi GM, et al. Postoperative adjuvant transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond the Milan criteria: a retrospective analysis. *Am J Cancer Res* 2014;5:450-457